The split verdict in the first trial of a pair of long-term Vioxx users’ cases against Merck & Co. would support its strategy of battling each claim rather than settling the more than 10,000 cases, litigators say.

Although an Atlantic City, N.J., jury said that the Whitehouse Station, N.J., pharmaceutical giant failed to adequately warn John McDarby, 77, and Thomas Cona, 60, of the heart risk factors of taking Vioxx, it awarded $13.5 million to McDarby and sent Cona home with only the $45 he had paid for the product. Both were long-term users of the drug. The latest results bring the trial tally to two wins apiece.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]